![]() Novartis Gene Therapies Novartis Gene Therapies (formerly known as AveXis) is a biotech company developing innovative treatments for rare and life-threatening genetic diseases. | ![]() ZIOPHARM Oncology ZIOPHARM Oncology is an American biopharmaceutical company developing novel therapeutics for the treatment of cancer. | Aera Therapeutics Aera Therapeutics is a biopharmaceutical company that develops transformative genetic medicines for modalities and therapeutic areas. | Jenthera Therapeutics Jenthera Therapeutics is a biotech company offering a cell-targeted nuclease approach for therapeutics that addresses the challenges faced by CRISPR-based gene editing. | ||
Founding Date | Founding Date 2010 | Founding Date 2005 | Founding Date 2014 | Founding Date 2021 | Founding Date 2019 |
Type | Type Subsidiary | Type Public | Type Private | Type Private | Type Private |
Tags | |||||
Locations | Locations Bannockburn, US HQ | Locations Boston, US HQ | Locations ES HQ Paterna, ES | Locations Boston, US HQ | Locations Montréal, CA HQ |
Employees | Employees 6603% decrease | Employees 7352% increase | Employees 15 | Employees 801% increase | Employees 3 |
Financial | |||||
Net income | Net income ($218.1m) (FY, 2017) | Net income ($4.2m) (FY, 2025) | Net income N/A | Net income N/A | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 344k (almost 8 years ago) | Latest funding round $ 193m (about 3 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 75m | Total funding raised $ 125.1m | Total funding raised $ 344k | Total funding raised $ 193m | Total funding raised N/A |

ZIOPHARM Oncology is an American biopharmaceutical company developing novel therapeutics for the treatment of cancer.
View companyAera Therapeutics is a biopharmaceutical company that develops transformative genetic medicines for modalities and therapeutic areas.
View companyJenthera Therapeutics is a biotech company offering a cell-targeted nuclease approach for therapeutics that addresses the challenges faced by CRISPR-based gene editing.
View company